COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/19/2025 15:34 PDT] COMPASS Pathways plc (NASDAQ:CMPS), Up By 100% ($3.79) From $3.79 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/12/2025 07:18 PDT] CMPS Expected to Trade Up After Bullish Patterns Develop
• [04/04/2025 11:07 PDT] COMPASS Pathways plc (NASDAQ:CMPS), Down By 100% ($3) From $3 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/25/2025 07:07 PDT] CMPS Expected to Trade Up After Bullish Patterns Develop
• [03/21/2025 07:10 PDT] CMPS Expected to Trade Down After Bearish Patterns Develop